On Tuesday, Red Hat Inc(NYSE:RHT)’s shares declined -2.99% to $70.04.
Red Hat, Inc. (RHT), the world’s leading provider of open source solutions, recently released findings from its recent mobile survey revealing trends in enterprise mobility hiring precedingities for 2015. According to the survey, 50 percent of organizations plan to hire for mobile positions this year. Of those organizations, 32 percent are focused on skills related to front-end development, with 27 percent looking for back-end integration skills and 15 percent seeking DevOps for mobile.
According to Gartner, “By the end of 2017, market demand for mobile app development services will grow at least five times faster than internal IT organizations’ capacity to deliver them.”1 Based on the survey results, Red Hat anticipates that organizations will continue to preceding hiring for these skills while also strengthening internal expertise in areas such as the Internet of Things (IoT), mobile project administration, and wearables.
Red Hat, Inc. provides open source software solutions to enterprise customers worldwide. It develops and offers operating system, virtualization, middleware, storage, and cloud technologies. The company’s products comprise Red Hat Enterprise Linux, an operating system platform that runs on hardware for use in physical, virtual, container, and cloud environments; Red Hat Enterprise Virtualization, which comprises standalone virtualization functionality and administration tools for server and desktop deployments; and Red Hat JBoss Middleware that offers middleware for developing, deploying, and managing applications, in addition to integrating applications, data and devices, and automating business processes.
Alamos Gold, Inc. (NYSE:AGI)’s shares gained 7.32% to $4.40.
Alamos Gold Inc. (AGI) stated financial results for the quarter ended June 30, 2015 and reviewed its operating, exploration and development activities.
Subsequent to the end of the second quarter, on July 2, 2015, Alamos Gold Inc. (“Former Alamos”) and AuRico Gold Inc. (“AuRico”) accomplished the formerly declared agreement to merge the two companies (the “Merger”). Accordingly, the financial statements and associated Administration’s Talk aboution and Analysis of both AuRico and Former Alamos for the three and six-month periods ended June 30, 2015 have been stated separately. For the purposes of this press release, the merged company, which retained the Alamos name, has comprised of the operating and financial results of both Former Alamos and AuRico. The first, second, third and fourth quarters of the Company’s fiscal year are referred to as “Q1”, “Q2”, “Q3” and “Q4”, respectively.
Alamos Gold, Inc. operates as an intermediate gold producer primarily in North America. The company primarily holds a 100% interest in the Young-Davidson gold mine, which comprises mineral leases and claims totaling 11,000 acres in Northern Ontario, Canada.
At the end of Tuesday’s trade, Manitowoc Company Inc (NYSE:MTW)‘s shares dipped -2.58% to $16.62.
The Manitowoc Company, Inc. (MTW) declared that it will release its second-quarter 2015 financial results on Wednesday, July 29, after the close of market. The company’s second-quarter results will also be talk about by Manitowoc’s administration team during a live conference call for security analysts and institutional investors, which will be held at 10:00 a.m., Eastern Time, on Thursday, July 30.
The Manitowoc Company, Inc. designs, manufactures, and sells cranes and related products, and foodservice equipment worldwide. The Cranes and Related Products segment offers lattice-boom cranes, counting crawler and truck mounted lattice-boom cranes, and crawler crane attachments; tower cranes comprising top slewing, luffing jib, topless, and self-erecting tower cranes; mobile telescopic cranes, such as rough terrain, all-terrain, truck mounted, and industrial cranes; and boom trucks comprising telescopic boom trucks under the Manitowoc, Potain, Grove, National Crane, and Shuttlelift brands. Its products are used in various applications, counting energy and utilities; petrochemical and industrial projects; infrastructure development, such as road, bridge, and airport construction; and commercial and high-rise residential construction.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ended its Tuesday’s trading session with -0.78% loss, and closed at $170.85.
Alexion Pharmaceuticals, Inc. (ALXN) declared financial results for the second quarter of 2015. Net product sales of Soliris® (eculizumab) grew to $636 million, a 24% enhance, contrast to $512.5 million for the same period in 2014, despite currency headwinds. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $1.44, contrast to $1.12 in the second quarter of 2014. On a GAAP basis, diluted EPS for the second quarter of 2015 was $0.83 per share, influenced by $40.1 million, or $0.20 per share, related to acquisition and restructuring costs resulting from the Synageva acquisition, contrast to $0.83 in the second quarter of 2014.
Second Quarter 2015 Financial Highlights
- Net product sales of Soliris®were $636 million contrast to $512.5 million in the same quarter last year.
- Non-GAAP R&D expense was $116.6 million contrast to $85.1 million in the same quarter last year. GAAP R&D expense was $131.7 million contrast to $92.6 million in the same quarter last year.
- Non-GAAP SG&A expense was $169.1 million contrast to $139.5 million in the same quarter last year. GAAP SG&A expense was $221.4 million contrast to $159.5 million in the same quarter last year.
- Non-GAAP effective tax rate was a benefit of 0.6% contrast to tax expense of 8.0% in the same quarter last year. In Q2 2015, the Company benefitted from the utilization of operating losses from Synageva in 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
